Amgen GmbH

Company

    • Company type:
      • Manufacturer
    • Year founded:
    • 1989
    • Employees (at the site):
    • 315
    • Turnover range:
    • 50m <125m EUR
    • Products/services:
    • Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.

    • Core competencies:
    • Amgen's corporate mission is to be the world leader in developing and delivering important, cost-effective therapeutics based on cellular and molecular biology. The company's first product, EPOGEN® (Epoetin alfa), stimulates and regulates the production of red blood cells. Amgen's second product, NEUPOGEN® (Filgrastim), is a recombinant granulocyte colony-stimulating factor (G-CSF) that selectively stimulates growth of infection-fighting white blood cells known as neutrophils. In 2001 Amgen launched a new drug, called Aranesp®, which also stimulates the production of red blood cells. Aranesp® was created by rational drug design and has a threefold longer halflife time compared to Epogen®. In 2002 AMGEN launched a second generation G-CSF called Neulasta® which also stimulates the growth of neutrophils. Neulasta® has an important advantage. Due to its pegylation Neulasta® has a longer half-life time and therefore has to be administered only once per chemotherapy cycle whereas Neupogen® has to be administered daily.

    • Language skills:
    • German
    • Key Tech / section:
      • Biotechnology: Molecular diagnostics for humans
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 46.75: Wholesale of chemical products
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Christopher McKinlay (Mr.)
      - Management

      Christophe Bourdon (Mr.)
      - Management